

PI Major Mutations:None

PI Accessory Mutations:None

PR Other Mutations:I15V 100%  
seen=121,311 • G16E 100%  
seen=23,003 • E35D 100%  
seen=11,011 • M36I 100%  
seen=11,019 • R57K 100%  
seen=12,190 • H69K 100%  
seen=10,130 • K70R 95%  
seen=10,139 • L89M 100%  
seen=10,000

Protease Inhibitors	
atazanavir/r (ATV/r)	Susceptible
darunavir/r (DRV/r)	Susceptible
fosamprenavir/r (FPV/r)	Susceptible
indinavir/r (IDV/r)	Susceptible
lopinavir/r (LPV/r)	Susceptible
nelfinavir (NFV)	Susceptible
saquinavir/r (SQV/r)	Susceptible
tipranavir/r (TPV/r)	Susceptible

No drug resistance mutations were found for PI.

NRTI Mutations:None

NNRTI Mutations:**K103N** 100%  
seen=9,000 • **H221HY** 1 RTV, 14 100%  
seen=9,111

RT Other Mutations:P4PH 1 RTV, 14 100%  
seen=9,110 • E6KR 6 RTV, 14 100%  
seen=26,102 • K11R 100%  
seen=26,100 • K20R 100%  
seen=21,100 • V21I 100%  
seen=21,109 • V35T 100%  
seen=21,100 • T39G 100%  
seen=21,100 • W88S 100%  
seen=11,090 • K122E 100%  
seen=11,088 • D123S 100%  
seen=10,763 • I135V 100%  
seen=10,770 • T165T 1 RTV, 1 100%  
seen=21,100 • K166KR 6 RTV, 6 100%  
seen=11,100 • K173A 100%  
seen=20,100 • D177E 100%  
seen=20,100 • V179I 100%  
seen=20,100 • I202V 100%  
seen=11,100 • V245Q 100%  
seen=4,100 • E248D 100%  
seen=4,100 • K275Q 100%  
seen=1,100 • K277R 100%  
seen=1,100 • T286A 100%  
seen=1,100 • E291D 100%  
seen=1,100 • I293V 100%  
seen=1,100 • P294T 100%  
seen=1,100 • E297A 100%  
seen=1,100 • E312D 100%  
seen=100 • I326V 1 RTV, 14 100%  
seen=210

Nucleoside Reverse Transcriptase Inhibitors		Non-nucleoside Reverse Transcriptase Inhibitors	
abacavir (ABC)	Susceptible	doravirine (DOR)	Potential Low-Level Resistance
zidovudine (AZT)	Susceptible	efavirenz (EFV)	High-Level Resistance
stavudine (D4T)	Susceptible	etravirine (ETR)	Potential Low-Level Resistance
didanosine (DDI)	Susceptible	nevirapine (NVP)	High-Level Resistance
emtricitabine (FTC)	Susceptible	rilpivirine (RPV)	Low-Level Resistance
lamivudine (3TC)	Susceptible		
tenofovir (TDF)	Susceptible		

- RT comments
- NNRTI
- K103N** is a non-polymorphic mutation that confers high-level reductions in NVP and EFV susceptibility. It is the most commonly transmitted DRM.
  - H221Y** is a non-polymorphic accessory mutation selected primarily by NVP, RPV, and DOR. It frequently occurs in combination with Y181C.
- Other
- V179I** is a polymorphic mutation that is frequently selected in persons receiving ETR and RPV. However, it has little, if any, direct effect on NNRTI susceptibility.
  - This virus is predicted to have low-level reduced susceptibility to **RPV**. The use of the combination of CAB/**RPV** should be considered to be relatively contraindicated.

No drug resistance mutations were found for NRTI.

Drug resistance mutation scores of NNRTI:

Download CSV

Rule	DOR ⚖	EFV ⚖	ETR ⚖	NVP ⚖	RPV ⚖
<u>H221HY</u>	10	10	10	15	15
<u>K103N</u>	0	60	0	60	0
Total	10	70	10	75	15